Psychotherapy

Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Use, Biomarker, Lists of diseases, Mindfulness, Psychotherapy, Research, Sonoran, Anxiety, Mental health, Depression, Phase II, TRD, Depression (mood), CEO, University of Oregon, Partnership, Treatment, Center, EARS, University, 5-Methoxy-N,N-diisopropyltryptamine, Brain, Beckley Foundation, Patient, Technology, Clinical trial, Serotonin, Collection, Psilocybin, Patient safety, Health, Pharmaceutical industry, Medical imaging

This latest partnership further strengthens Beckley Psytechs digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Key Points: 
  • This latest partnership further strengthens Beckley Psytechs digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, said: This partnership with Ksana Health further supports our strategy to develop an integrated psychedelic treatment model, ensuring that patients are continuously supported throughout their treatment journey.
  • We look forward to working with Ksana Health and exploring how their state-of-the-art digital technology can help support patient safety and response in our upcoming Phase 2 clinical trials.
  • We are therefore very excited to partner with Beckley Psytech to help them build out their digital strategy.

HMP Global Solidifies Position as World's Largest Producer of Cardiovascular Events and Education with Acquisition of Renowned Western Atrial Fibrillation Symposium

Retrieved on: 
Monday, June 13, 2022
Argentum, Conference, Amputation, Cardiology, VRTX, AF, International Symposium on Endovascular Therapy, ISET, Symposium, Faculty, Marketing, CEO, Partnership, Elderly care, EMS, Diagnosis, Learning, AMP, EMT, Digital journalism, Physician, Health, Patient, Acquisition, Electrophysiology, SMASH, Internal medicine, Education, Research, News, Disease, Senior living, Practitioner, Growth, Student, CIO, Clinical trial, CLI, Atrial fibrillation, Evolution, SAWC, LINC, Pharmaceutical industry, Medicine, Silver, MD, Psychotherapy

MALVERN, Pa., June 13, 2022 /PRNewswire-PRWeb/ -- HMP Global, the world's largest healthcare event and education company, today announced it has entered into a partnership to produce the Western Atrial Fibrillation Symposium, the premier educational event focused exclusively on atrial fibrillation (AF).

Key Points: 
  • Now in its 16th year, the Western Atrial Fibrillation Symposium takes place annually in February in Park City, Utah.
  • "Sixteen years ago, we created the Western Atrial Fibrillation Symposium with the vision of offering a robust outlet to advance an integrated approach to understanding and treating atrial fibrillation," said Nassir Marrouche, MD, internationally renowned electrophysiologist, and symposium director.
  • Beginning in 2023, the Western Atrial Fibrillation Symposium will benefit from the strength and expertise HMP Global brings in medical meeting management, education, and marketing.
  • The partnership with Western Atrial Fibrillation Symposium continues a period of accelerated growth for HMP Global.

Numinus completes acquisition of Novamind and announces executive appointments

Retrieved on: 
Saturday, June 11, 2022
Mission statement, Psychotherapy, Time, Company, Lists of diseases, Trauma, Pain, Toronto Stock Exchange, Medical director, Certification, Psycho-oncology, Psychedelic therapy, University, RSU, Cancer, CSE, Canadian Securities Exchange, Depression, Legislation, Transaction, CEO, Partnership, Center, Par value, Multidisciplinary Association for Psychedelic Studies, MD, Psychiatry, MAPS, Indian stock exchange, SEDAR, Experiential learning, Anxiety, Supreme Court of British Columbia, Patient, Alternative, Acquisition, TSX, Ketamine, California Institute for Quantitative Biosciences, Research, News, FDA, Growth, Clinic, Brigham Young University, Risk, Nursing care plan, Cost-exchange ratio, Opioid use disorder, Medicine, Pharmaceutical industry, Security (finance), Esketamine, List of cosmic entities in Marvel Comics, BC

This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.

Key Points: 
  • This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.
  • Numinus is also pleased to announce the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind.
  • As approved by shareholders on June 8, 2022, Numinus has issued 43,474,659 common shares to the former shareholders and RSU holders of Novamind, as consideration for the acquisition representing 0.84 of one (the "Exchange Ratio") Numinus common share per each Novamind share and Novamind restricted share unit (RSU).
  • Given securities processing times, these Numinus shares should settle in Novamind investor accounts by June 16, 2022.

Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022

Retrieved on: 
Thursday, June 9, 2022
Mission statement, Contract research organization, Psychotherapy, DMT, Company, Program, IV, Patent, Pharmacokinetics, Depression, MDD, Health care, IM, Mammal, International, Pharma, Brain, Development, Indian stock exchange, GLOBE, Patient, Phase, European Medicines Agency, Clinical trial, Plant, International Financial Reporting Standards, Lists of diseases, Safety, SEDAR, Pharmaceutical industry, Potash, Medical device

LONDON, June 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the fiscal year ended February 28, 2022. A complete copy of the audited consolidated financial statements prepared in accordance with International Financial Reporting Standards and the corresponding management’s discussion and analysis can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are in Canadian dollars. 

Key Points: 
  • LONDON, June 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the fiscal year ended February 28, 2022.
  • Cash used in operating activities of $16.2 million for the 12 months ended February 28, 2022.
  • Operating expenses for the 12 months ended February 28, 2022 were $18.1 million.
  • Small Pharma is advancing a pipeline of DMT-based therapies and is leading the most advanced clinical trial in commercial development for DMT-assisted psychotherapy in MDD.

Aggrego Oncology enhances premier news and information hub for oncology physicians, clinicians

Retrieved on: 
Thursday, June 9, 2022
EMT, News, Health, VRTX, Review, EMS, Evolution, Education, Symposium, SAWC, LINC, Medicine, Psychotherapy

MALVERN, Pa. , June 9, 2022  /PRNewswire-PRWeb/ -- Aggrego Oncology, the leading source for high-quality oncology and healthcare news and information, now offers an enhanced experience for physicians and clinicians in the oncology field. The updates launched on June 3, making the premier oncology information hub even stronger with powerful new features allowing site users to self-publish their work and interact with colleagues.

Key Points: 
  • Users can register on the site, create a profile, and submit their own articles and blogs for review and publication.
  • It offers access to practical continuing education opportunities.
  • Users can also comment on articles, send private messages to other site users, and share ideas, network, and collaborate without leaving the platform.
  • HMP Global is the force behind Healthcare Made Practical and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care.

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Retrieved on: 
Wednesday, June 8, 2022
Keynote, Psychotherapy, CSE, Research, Biotechnology, Mental health, Doctor of Philosophy, WESA, CEO, Advocate, Therapy, Government, GLOBE, DSM-5, Work, COVID-19, Addiction, Drug development, Substance Abuse, Pharmaceutical industry

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe, accelerate their research and drug development efforts.

Key Points: 
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe, accelerate their research and drug development efforts.
  • Mr. Carcillos keynote, From Advocate to Executive: How my patient experience influences my work as CEO, will cover his personal experience with psychedelic treatments and the inspiration that led him to found and lead Wesana.
  • He will explore how he transformed himself from patient to advocate, to an inspiring leader.
  • loss, stress, isolation, and treatment disruption has only exacerbated the number of people struggling with their mental health.

Pasadena Villa Outpatient Mental Health Treatment Clinic Opens in Norfolk, Virginia

Retrieved on: 
Tuesday, June 7, 2022
Hospital, PTSD, Psychotherapy, Insurance, Lists of diseases, Mental health, Anxiety, CEO, Partnership, Bed, GLOBE, Addiction, Personality, Bipolar disorder, Post-traumatic stress disorder, Medicine, Odyssey

BRENTWOOD, Tenn., June 07, 2022 (GLOBE NEWSWIRE) -- Odyssey Behavioral Healthcare ("Odyssey") is pleased to announce the opening of its newest Pasadena Villa Outpatient location in Norfolk , Virginia.

Key Points: 
  • BRENTWOOD, Tenn., June 07, 2022 (GLOBE NEWSWIRE) -- Odyssey Behavioral Healthcare ("Odyssey") is pleased to announce the opening of its newest Pasadena Villa Outpatient location in Norfolk , Virginia.
  • This is the seventh Pasadena Villa Outpatient location and the third in Virginia.
  • Developed to address an underserved market need, the Norfolk location will offer treatment to individuals facing mental health and co-occurring disorders.
  • "The Odyssey Outpatient Network is addressing the region's significant demand for evidence-based mental health outpatient treatment.

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

Retrieved on: 
Friday, June 3, 2022
Company, Anxiety, Psychotherapy, Form, Depression, Forward-looking statement, CEO, Security (finance), Media, Failure, U.S. Securities and Exchange Commission, Nursing, Therapy, Physician, FDA, Risk, Patient, Private Securities Litigation Reform Act, Ketamine, SEC, Engineering, Instagram, Post-traumatic stress disorder, Safety, Pharmaceutical industry, Public relations

The KetaDASH Mobile Unit is specifically designed to focus on safety, setting, comfort and efficacy of treatments.

Key Points: 
  • The KetaDASH Mobile Unit is specifically designed to focus on safety, setting, comfort and efficacy of treatments.
  • This innovative service departs from in-clinic intravenous, treatment or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision.
  • A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient's home.
  • Mr. Kaplan continued, I am honored to include pictures of our KetaDASH Mobile Unit, which we created together.

Psyence Group Corporate Update

Retrieved on: 
Thursday, June 2, 2022
Chief of Army Staff (Pakistan), Psychotherapy, OTCQB, Company, Contract research organization, Doctor of Philosophy, Radio Cooperativa, Group, Clerkenwell, Sale, Neurology, Medical director, Wellness, Pharmacy, Drug development, CSE, Marketing, Canadian Securities Exchange, MBA, Depression, Filament, Palliative care, Potential, Coffee, Quality assurance, Development, Health Canada, CAD, CRO, United Kingdom, Investment banking, Mycology, Anxiety, Mental health, Partner, Medicine, Anxiety disorder, Psilocybin, Psychological trauma, Exercise, Science, Research, Proceeds of Crime Act 2002, Nature, API, Therapy, FDA, Growth, GLOBE, Risk, Research and development, Clinical trial, Crime, Drink, Person, Safety, Pharmaceutical industry, Medical device, Oil, MD, Psyence, Angus Goodleaf

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function. The Psyence Group develops and provides innovative, safe, and effective psychedelic and nature-centered solutions for mental health and palliative care.

Key Points: 
  • Partnership with CRO Clerkenwell Health to design and deliver Psyences UK clinical trial progressing; exclusive licensing agreement with Filament Health
    Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
    Exploring capital market initiatives in UK, hires Investment Bank
    TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (Psyence or the Company) is pleased to provide the following corporate update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.
  • The Psyence Group develops and provides innovative, safe, and effective psychedelic and nature-centered solutions for mental health and palliative care.
  • In addition, Psyence appointed Dr. Clive Ward-Able as Medical Director, Head of Research & Development and Early Commercialization for Psyence in December 2021.
  • Our key divisions, Psyence Production, Psyence Therapeutics and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Southern Africa, and a presence in the United States and Australia.

HOPE Center Harlem to Honor Mental Health Heroes at Annual Event

Retrieved on: 
Monday, June 6, 2022
Linda, Community engagement, The Kristin Brooks Hope Center, Social work, COVID, Mental health, National Alliance on Mental Illness, Child, Central, Mental disorder, Psychiatry, Breakfast, HOPE, Solution, Adolescence, 2004 Democratic National Convention keynote address, Seventh Avenue, National Alliance, Carnegie Hall, NYU, Male, Psychotherapy, Department, United States Public Health Service, Institute, Color, Mental Hygiene, Doctorate, Mental Health Research Institute (Melbourne), Health, Medicine

NEW YORK, June 6, 2022 /PRNewswire/ -- Local and national mental health leaders will be celebrated at the HOPE Center Harlem's HOPE in Action Fundraising Awards Breakfast on June 17. Among those being honored at the 3rd annual event, sponsored by Sugar Hill Capital Partners, are Dr. Torian Easterling, First Deputy Commissioner and Chief equity Officer at the New York City Department of Health & Mental Hygiene, and Rawle Andrews Jr., Executive Director of the American Psychiatric Association Foundation (APAF).

Key Points: 
  • NEW YORK, June 6, 2022 /PRNewswire/ -- Local and national mental health leaders will be celebrated at the HOPE Center Harlem's HOPE in Action Fundraising Awards Breakfast on June 17.
  • Given the growing mental health crisis in the wake of the COVID pandemic, the urgency to identify new treatments and solutions has never been greater, the HOPE Center noted.
  • The breakfast brings together a distinguished group of doctors, mental health scholars, researchers, clinicians, and advocates who have contributed greatly to addressing the health & mental health challenges of our time.
  • The HOPE Center offers free mental health services for individuals, families, and group therapy for adults and teens focused on suicide prevention.